Goldman Sachs’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.28M | Sell |
669,719
-124,243
| -16% | -$801K | ﹤0.01% | 3858 |
|
|
2025
Q4 | $4.72M | Buy |
793,962
+559,345
| +238% | +$2.97M | ﹤0.01% | 3800 |
|
|
2025
Q3 | $1.25M | Buy |
234,617
+32,588
| +16% | +$138K | ﹤0.01% | 4879 |
|
|
2025
Q2 | $693K | Sell |
202,029
-92,214
| -31% | -$294K | ﹤0.01% | 4956 |
|
|
2025
Q1 | $871K | Sell |
294,243
-19,854
| -6% | -$62.1K | ﹤0.01% | 4798 |
|
|
2024
Q4 | $958K | Buy |
314,097
+8,379
| +3% | +$24.4K | ﹤0.01% | 4848 |
|
|
2024
Q3 | $780K | Buy |
305,718
+105,134
| +52% | +$318K | ﹤0.01% | 4809 |
|
|
2024
Q2 | $654K | Sell |
200,584
-249,996
| -55% | -$1.1M | ﹤0.01% | 4681 |
|
|
2024
Q1 | $2.39M | Buy |
450,580
+334,625
| +289% | +$1.8M | ﹤0.01% | 3743 |
|
|
2023
Q4 | $502K | Buy |
115,955
+31,811
| +38% | +$105K | ﹤0.01% | 4754 |
|
|
2023
Q3 | $221K | Buy |
84,144
+10,230
| +14% | +$34.8K | ﹤0.01% | 5009 |
|
|
2023
Q2 | $261K | Sell |
73,914
-90
| -0.1% | -$281 | ﹤0.01% | 5080 |
|
|
2023
Q1 | $229K | Sell |
74,004
-2,447
| -3% | -$9.23K | ﹤0.01% | 5238 |
|
|
2022
Q4 | $323K | Sell |
76,451
-43,081
| -36% | -$149K | ﹤0.01% | 5108 |
|
|
2022
Q3 | $284K | Sell |
119,532
-101,360
| -46% | -$296K | ﹤0.01% | 5324 |
|
|
2022
Q2 | $629K | Sell |
220,892
-218,942
| -50% | -$544K | ﹤0.01% | 4922 |
|
|
2022
Q1 | $1.27M | Sell |
439,834
-1,843,331
| -81% | -$4.77M | ﹤0.01% | 4641 |
|
|
2021
Q4 | $6.94M | Buy |
2,283,165
+1,475,239
| +183% | +$6.4M | ﹤0.01% | 3108 |
|
|
2021
Q3 | $5.66M | Buy |
807,926
+421,366
| +109% | +$3.16M | ﹤0.01% | 3248 |
|
|
2021
Q2 | $3.55M | Sell |
386,560
-438,902
| -53% | -$4.45M | ﹤0.01% | 3665 |
|
|
2021
Q1 | $8.02M | Buy |
825,462
+127,529
| +18% | +$1.42M | ﹤0.01% | 2745 |
|
|
2020
Q4 | $7.16M | Sell |
697,933
-209,147
| -23% | -$2.12M | ﹤0.01% | 2716 |
|
|
2020
Q3 | $9.15M | Sell |
907,080
-77,600
| -8% | -$790K | ﹤0.01% | 2405 |
|
|
2020
Q2 | $10.3M | Buy |
984,680
+291,227
| +42% | +$3.01M | ﹤0.01% | 2253 |
|
|
2020
Q1 | $5.85M | Sell |
693,453
-74,616
| -10% | -$725K | ﹤0.01% | 2520 |
|
|
2019
Q4 | $6.72M | Sell |
768,069
-217,913
| -22% | -$1.8M | ﹤0.01% | 2734 |
|
|
2019
Q3 | $10.6M | Buy |
985,982
+465,063
| +89% | +$5.02M | ﹤0.01% | 2280 |
|
|
2019
Q2 | $6.62M | Sell |
520,919
-191,182
| -27% | -$4.4M | ﹤0.01% | 2645 |
|
|
2019
Q1 | $27.6M | Buy |
712,101
+366,594
| +106% | +$11.2M | 0.01% | 1587 |
|
|
2018
Q4 | $7.03M | Buy |
345,507
+101,932
| +42% | +$3.06M | ﹤0.01% | 2612 |
|
|
2018
Q3 | $11.2M | Buy |
243,575
+5,346
| +2% | +$258K | ﹤0.01% | 2370 |
|
|
2018
Q2 | $14.1M | Buy |
238,229
+49,483
| +26% | +$2.87M | ﹤0.01% | 2160 |
|
|
2018
Q1 | $12.8M | Sell |
188,746
-311,640
| -62% | -$23.3M | ﹤0.01% | 2156 |
|
|
2017
Q4 | $49.5M | Buy |
500,386
+2,232
| +0.4% | +$250K | 0.01% | 1296 |
|
|
2017
Q3 | $59.7M | Buy |
498,154
+23,437
| +5% | +$2.18M | 0.01% | 1155 |
|
|
2017
Q2 | $41.5M | Buy |
474,717
+158,636
| +50% | +$8.87M | 0.01% | 1363 |
|
|
2017
Q1 | $11.8M | Buy |
316,081
+140,814
| +80% | +$5.14M | ﹤0.01% | 2284 |
|
|
2016
Q4 | $5.38M | Buy |
175,267
+19,771
| +13% | +$855K | ﹤0.01% | 2986 |
|
|
2016
Q3 | $10.4M | Buy |
155,496
+21,774
| +16% | +$1.1M | ﹤0.01% | 2418 |
|
|
2016
Q2 | $3.98M | Buy |
133,722
+42,649
| +47% | +$1.33M | ﹤0.01% | 3046 |
|
|
2016
Q1 | $2.67M | Sell |
91,073
-111,497
| -55% | -$5.04M | ﹤0.01% | 3222 |
|
|
2015
Q4 | $15.9M | Buy |
202,570
+134,690
| +198% | +$10.6M | 0.01% | 1921 |
|
|
2015
Q3 | $5.12M | Sell |
67,880
-144,070
| -68% | -$13.6M | ﹤0.01% | 2869 |
|
|
2015
Q2 | $24.7M | Buy |
211,950
+47,098
| +29% | +$8.53M | 0.01% | 1632 |
|
|
2015
Q1 | $38.9M | Buy |
164,852
+135,606
| +464% | +$29M | 0.01% | 1284 |
|
|
2014
Q4 | $5.54M | Buy |
29,246
+5,996
| +26% | +$1.33M | ﹤0.01% | 2903 |
|
|
2014
Q3 | $5.55M | Sell |
23,250
-14,492
| -38% | -$2.98M | ﹤0.01% | 2912 |
|
|
2014
Q2 | $2.49M | Buy |
37,742
+31,268
| +483% | +$2.22M | ﹤0.01% | 3767 |
|
|
2014
Q1 | $674K | Buy |
6,474
+3,633
| +128% | +$427K | ﹤0.01% | 5023 |
|
|
2013
Q4 | $294K | Sell |
2,841
-18,357
| -87% | -$1.08M | ﹤0.01% | 5710 |
|
|
2013
Q3 | $1.14M | Buy |
21,198
+11,016
| +108% | +$594K | ﹤0.01% | 4481 |
|
|
2013
Q2 | $452K | Buy |
+10,182
| New | +$359K | ﹤0.01% | 5026 |
|
Other funds holding PBYI
ACA
VCM
VPM
Goldman Sachs's PBYI Position: Q1 2026 in Review
Goldman Sachs reduced its Puma Biotechnology (PBYI) stake by 16% in Q1 2026, selling an estimated $801K and leaving 669,719 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3858.
Goldman Sachs first reported a position in PBYI in Q2 2013 and has held it in 52 quarters since. The position peaked at $59.7M in Q3 2017. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.
- Goldman Sachs held 669,719 shares of Puma Biotechnology worth $4.28M as of Q1 2026.
- Goldman Sachs sold 124,243 Puma Biotechnology shares in Q1 2026, an estimated $801K.
- Puma Biotechnology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3858 holding.
- Goldman Sachs first reported a position in Puma Biotechnology in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Puma Biotechnology position peaked at $59.7M in Q3 2017.
- 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.